BSE 1654.55 NSE 1653.55

Global Manufacturing

Delivering high quality. Delivering on our promise

Lupin’s global manufacturing footprint helps us deliver quality-assured products to our customers around the world. Our investments in manufacturing capital shape our vision of creating affordable, quality medicines that address unmet patient needs. In line with our growth strategy, we continue to ramp up capacities and automation to support our pipeline of complex generics and biotechnology products.

Recently, we created capacities in several new areas, including the high-potency product manufacturing block at Indore Unit I, a state-of-the-art plant for Metered Dose Inhalers (MDI) at Indore Unit III, the Pyrazinamide API block at the Visakhapatnam unit, a new hi-tech facility for Oral Solid Dose (OSD) formulations and injectables at the Nagpur SEZ unit, and the multi-fold expansion of our Biotech Drug Substance facility in Pune, among others.


Technology is the mainstay of our manufacturing capabilities, with digital being a key pillar of our strategy. We have invested in manufacturing automation to maintain quality and productivity at the highest levels. Our plants, and the expertise of our people running them, help Lupin maintain benchmark standards in manufacturing quality.


Environment Health and Safety

Industry best Environment, Health and Safety (EHS) practices enables Lupin to standout from competition and ensure sustainable growth. All Lupin’s plants are cGMP compliant and have made substantial investments in upgrading infrastructure to meet the constantly evolving EHS standards.


Manufacturing Sites

Our 15 state-of-the-art manufacturing facilities are spread across India, the United States, Brazil and Mexico. These manufacturing sites are equipped with modern production facilities and are designed to meet the required regulatory norms. Our sites are regularly inspected by national and international authorities to ensure 24×7 compliance and conformance.


COVID-19 has led the pharmaceutical sector to reassess global supply chains. With less than 30% dependence on early raw materials and intermediates from China, our supply chain strategy ensured that we remained insulated from supply disruption caused by the pandemic. At the peak of the disruption in April 2020, Lupin sites continued to deliver 90% of their formulations target and 120% of their API target. Throughout the pandemic, our sites cleared the highest regulatory approvals and continued to deliver safely on customer commitments. It is our strong manufacturing base that gives Lupin a superior advantage as a leading and reliable contributor of quality pharmaceutical products.